AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 17:13:00 EET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
Andersen Consulting Enhances Platform with Peers Technology + Consulting1.12.2025 16:30:00 EET | Press release
Andersen Consulting adds collaborating firm Peers Consulting + Technology, a Brazilian firm known for accelerating strategic change through digital innovation and advanced analytics. Founded in 2012, Peers delivers end-to-end services that combine strategic insight with digital execution. Its offerings span advanced analytics and generative AI, IT strategy, customer experience, finance, cybersecurity, sustainability, supply chain, M&A, and organizational transformation. Recognized for its impact across Latin America, Peers equips clients to modernize operations, enhance decision-making, and drive sustainable performance. “We believe meaningful transformation happens at the intersection of data, technology, and human insight,” said Managing Partner Pedro Ribeiro. “We work side by side with our clients to turn challenges into growth. Collaborating with Andersen Consulting enables us to extend that approach globally and help more organizations navigate complexity with clarity and speed.”
Rimini Street Announces Additional Stock Repurchase Transactions1.12.2025 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201195169/en/ Rimini Street Announces Additional Stock Repurchase Transactions Share Repurchases The Company repurchased a total of 975,000 shares of common stock to date in the fourth fiscal quarter of 2025, for approximately $3.8 million with an average per share purchase price of $3.92, reducing outstanding shares by approximately 1.1%1. The Company has now completed and announced $13.3 million in common stock repurchases under its $50 million Common Stock Repurchase Plan that was approved by the Rimini Street Board of Directors in February 2022 and recently extended through June 2029. $7.6 million of common stock repurchase
MVNO Europe - Europe's Competitiveness Depends on a Truly Open Telecoms Market, Not on Increased Concentration That Benefits a Handful of Mobile Operators1.12.2025 15:37:00 EET | Press release
This is the warning that MVNO Europe – through its President Jacques Bonifay – has issued to the European Commission in an open letter to Ursula von der Leyen and Vice-President Henna Virkkunen. As discussions on the Digital Networks Act (DNA) enter their decisive phase, the association, which brings together alternative mobile operators in Europe, points out that the EU's digital ambition can only be achieved if competition remains a structuring principle, not an adjustment variable. While some players are calling for "necessary" consolidation in the sector, MVNO Europe warns against a simplistic and economically dangerous vision. "Reducing the number of operators has never guaranteed innovation, access for European industries, or fair conditions for new digital services. On the contrary, the historical driver of European competitiveness has always been the diversity of players, models, technologies and services," says Jacques Bonifay, President of MVNO Europe and CEO of Transatel. Re
IonQ and CCRM Announce Strategic Quantum-Biotech Collaboration to Accelerate Development of Advanced Therapeutics1.12.2025 14:30:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201706303/en/ IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network. With more than 100,000 square feet of good manufacturing practice (GMP) facilities, 300+ scientific staff and a global network of academic and industry partners, CCRM is one of the world’s leading accelerators for advanced therapies. CCRM was established in 2011 in Toronto, Canada, to rea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom